Carlos Massayuki Kikuti

This paper develops a selective non-muscle myosin II inhibitor, MT-228, with high brain penetration and efficacy in preclinical models, offering therapeutic potential for diseases like stimulant use disorder.

This study shows Omecamtiv mecarbil and Mavacamten target the same myosin pocket but have antagonistic effects on heart contraction through structural and simulation analyses.